PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2022; 12(17):7641. doi:10.7150/thno.77886 This issue Cite

Erratum

Highly sensitive magnetic particle imaging of vulnerable atherosclerotic plaque with active myeloperoxidase-targeted nanoparticles

Wei Tong1,2,3,#, Hui Hui3,4,#, Corresponding address, Wenting Shang3,4,#, Yingqian Zhang2,#, Feng Tian2, Qiang Ma2, Xin Yang3,4, Jie Tian3,4,5, Corresponding address, Yundai Chen1,2, Corresponding address

1. Medical School of Chinese PLA, Chinese PLA General Hospital, Beijing, 100853, China.
2. Department of Cardiology, the Sixth Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China.
3. CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China.
4. University of Chinese Academy of Sciences, Beijing, China.
5. Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine, Beihang University, Beijing, 100083, China.
#These authors contributed equally to this work.

✉ Corresponding authors: Email address: hui.huiac.cn (Hui Hui), jie.tianac.cn (Jie Tian), cyundai163.com (Yundai Chen, Tel: +86‐10‐55499009, Fax: +86‐10‐55499209)

Citation:
Tong W, Hui H, Shang W, Zhang Y, Tian F, Ma Q, Yang X, Tian J, Chen Y. Highly sensitive magnetic particle imaging of vulnerable atherosclerotic plaque with active myeloperoxidase-targeted nanoparticles. Theranostics 2022; 12(17):7641. doi:10.7150/thno.77886. https://www.thno.org/v12p7641.htm
Other styles

File import instruction

Corrected-article in Theranostics, Volume 11, 506

 

The authors apologize that the original version of our paper unfortunately contained an incorrect representative image in Figure 4A, where the fluorescence image of an ApoE-/- mouse acquired at 24 h post-injection was saved twice using different color scale bars of fluorescence intensity. We apologize that, during the image assembly, the fluorescence image acquired at 24 h post-injection was mistakenly chosen as the fluorescence image acquired before injection of 5HFeC NPs. The correct version of the Figure 4A is shown below. We confirm that this correction does not affect any original results and conclusions of the paper. The authors apologize for any inconvenience that the errors may have caused.

 Figure 4A 

(Corrected) In vivo fluorescence image of active MPO in aorta atheroma of ApoE-/- mice before, and 24 h post, injection of 5HFeC NPs.

Theranostics Image

Author contact

Corresponding address Corresponding authors: Email address: hui.huiac.cn (Hui Hui), jie.tianac.cn (Jie Tian), cyundai163.com (Yundai Chen, Tel: +86‐10‐55499009, Fax: +86‐10‐55499209)

Published 2022-11-2

Citation styles

APA
Tong, W., Hui, H., Shang, W., Zhang, Y., Tian, F., Ma, Q., Yang, X., Tian, J., Chen, Y. (2022). Highly sensitive magnetic particle imaging of vulnerable atherosclerotic plaque with active myeloperoxidase-targeted nanoparticles. Theranostics, 12(17), 7641. https://doi.org/10.7150/thno.77886.

ACS
Tong, W.; Hui, H.; Shang, W.; Zhang, Y.; Tian, F.; Ma, Q.; Yang, X.; Tian, J.; Chen, Y. Highly sensitive magnetic particle imaging of vulnerable atherosclerotic plaque with active myeloperoxidase-targeted nanoparticles. Theranostics 2022, 12 (17), 7641. DOI: 10.7150/thno.77886.

NLM
Tong W, Hui H, Shang W, Zhang Y, Tian F, Ma Q, Yang X, Tian J, Chen Y. Highly sensitive magnetic particle imaging of vulnerable atherosclerotic plaque with active myeloperoxidase-targeted nanoparticles. Theranostics 2022; 12(17):7641. doi:10.7150/thno.77886. https://www.thno.org/v12p7641.htm

CSE
Tong W, Hui H, Shang W, Zhang Y, Tian F, Ma Q, Yang X, Tian J, Chen Y. 2022. Highly sensitive magnetic particle imaging of vulnerable atherosclerotic plaque with active myeloperoxidase-targeted nanoparticles. Theranostics. 12(17):7641.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use